LON:TRX - Tissue Regenix Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 6.08 0.00 (0.00 %)
(As of 05/20/2019 04:00 PM ET)
Previous CloseGBX 6.08
Today's RangeGBX 5.91 - GBX 6.09
52-Week RangeGBX 5.40 - GBX 12
Volume141,092 shs
Average Volume69,362 shs
Market Capitalization£70.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and Cardiac divisions. The company's decellularisation (dCELL) technology removes DNA and other cellular material from animal and human tissue leaving intact an inert acellular matrix upon which the patient's cells can repopulate. Its dCELL technology has applications in various clinical needs, such as wound care, and heart valve replacement. It offers DermaPure used for the treatment and management of complex and chronic wounds; and SurgiPure XD for the repair of hernias and/or body wall defects, which require the use of reinforcing or buttressing material to obtain the desired surgical outcome. The company is also developing OrthoPure XM, which makes the implant biocompatible and provides a biomechanically appropriate scaffold for cellular repopulation and eventual regeneration in the partial meniscectomy; OrthoPure XT and OrthoPure HT used for the anterior cruciate ligament injuries; and CardioPure for the replacement of human aortic and pulmonary valves. Tissue Regenix Group plc was incorporated in 2006 and is based in Leeds, the United Kingdom.

Receive TRX News and Ratings via Email

Sign-up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1904-567609

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£9.46 million
Cash FlowGBX 1.06 per share
Book ValueGBX 3.10 per share

Profitability

Miscellaneous

Employees100
Outstanding Shares1,155,619,968
Market Cap£70.20 million
Next Earnings DateN/A
OptionableOptionable

Tissue Regenix Group (LON:TRX) Frequently Asked Questions

What is Tissue Regenix Group's stock symbol?

Tissue Regenix Group trades on the London Stock Exchange (LON) under the ticker symbol "TRX."

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group PLC (LON:TRX) issued its quarterly earnings data on Monday, March, 26th. The company reported ($1.00) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.30) by $0.30. The company earned $5.23 million during the quarter. View Tissue Regenix Group's Earnings History.

Has Tissue Regenix Group been receiving favorable news coverage?

News headlines about TRX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tissue Regenix Group earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Tissue Regenix Group's key competitors?

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include TransEnterix (TRXC), Argos Therapeutics (ARGSQ), Swedbank (SWDBY), ArQule (ARQL), WisdomTree Middle East Dividend Fund (GULF), Starbucks (SBUX), SCYNEXIS (SCYX), Summit Financial Group (SMMF), Trevena (TRVN) and The Ultimate Software Group (ULTI).

Who are Tissue Regenix Group's key executives?

Tissue Regenix Group's management team includes the folowing people:
  • Mr. Steven Couldwell, CEO & Director (leave of Absence) (Age 58)
  • Mr. Gareth Hywel Jones, CFO, Company Sec. & Exec. Director (Age 50)
  • Mr. Mike Izon, Technical Director
  • Caitlin Pearson, Head of Communications
  • Mr. Joel Pickering, Pres of Tissue Regenix Wound Care Inc

How do I buy shares of Tissue Regenix Group?

Shares of TRX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tissue Regenix Group's stock price today?

One share of TRX stock can currently be purchased for approximately GBX 6.08.

How big of a company is Tissue Regenix Group?

Tissue Regenix Group has a market capitalization of £70.20 million and generates £9.46 million in revenue each year. Tissue Regenix Group employs 100 workers across the globe.

What is Tissue Regenix Group's official website?

The official website for Tissue Regenix Group is http://www.tissueregenix.com/.

How can I contact Tissue Regenix Group?

Tissue Regenix Group's mailing address is Innovation Way, YORK, YO10 5NY, United Kingdom. The company can be reached via phone at +44-1904-567609.


MarketBeat Community Rating for Tissue Regenix Group (LON TRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Tissue Regenix Group and other stocks. Vote "Outperform" if you believe TRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel